Several studies suggest that the baseline cePD-L1 levels are inversely correlated with the efficacy of first- or second-line anti-PD-1 or adjuvant anti-PD-(L)1 immunotherapy in metastatic melanoma patients, NSCLC, and others [285]. Here, CD274 is linked to metastatic melanoma.